Precigen Triple-Gene Provides Six-month Follow-up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart Failure

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. SPY
2. USO
3. IONQ
4. QCOM
5. IONS
6. ROIV
7. ORCL
8. AAPL
9. HOOD
10. NVS

Go back to Precigen Triple-Gene Provides Six-month Follow-up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart Failure
(NASDAQ: PGEN) Delayed: 6.87 --0 (-0%)
Previous Close $6.87    52 Week High $ 
Open $6.87    52 Week Low $ 
Day High $6.87    P/E N/A 
Day Low $6.87    EPS $ 
Volume 1,042